

VALEANT PHARMACEUTICALS INTERNATIONAL
Form SC 13G
February 10, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*

VALEANT PHARMACEUTICALS INTERNATIONAL
(Name of Issuer)

COMMON STOCK, \$0.01 PAR VALUE PER SHARE
(Title of Class of Securities)

91911X104
(CUSIP Number)

JANUARY 31, 2006
(Date of Event which Requires Filing
of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages
Page 1 of 9 Pages

1 Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)

PERRY CORP.

2 Check the Appropriate Box If a Member of a Group (See Instructions)
a.
b.

3 SEC Use Only

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G

4 Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned By Each Reporting Person With	5	Sole Voting Power 4,175,528
	6	Shared Voting Power 0
	7	Sole Dispositive Power 4,175,528
	8	Shared Dispositive Power 0

9 Aggregate Amount Beneficially Owned by Each Reporting Person

4,175,528

10 Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

[]

11 Percent of Class Represented By Amount in Row (9)

4.38%

12 Type of Reporting Person (See Instructions)

IA, CO

1 Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)

RICHARD C. PERRY

2 Check the Appropriate Box If a Member of a Group (See Instructions)

a. []
b. []

3 SEC Use Only

4 Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned By Each Reporting Person With	5	Sole Voting Power 4,175,528
	6	Shared Voting Power 0
	7	Sole Dispositive Power 4,175,528
	8	Shared Dispositive Power

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G

0

9 Aggregate Amount Beneficially Owned by Each Reporting Person
4,175,528

10 Check Box If the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)
[]

11 Percent of Class Represented By Amount in Row (9)
4.38%

12 Type of Reporting Person (See Instructions)
IN, HC

ITEM 1(a) NAME OF ISSUER:

Valeant Pharmaceuticals International (the "Issuer").

ITEM 1(b) ADDRESS OF THE ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

330 Hyland Avenue
Costa Mesa, CA 92626

ITEM 2(a) NAME OF PERSON FILING:

This statement is filed on behalf of each of the following persons
(collectively, the "Reporting Persons"):

- i) Perry Corp.; and
- ii) Richard C. Perry, in his capacities as the President and sole
stockholder of Perry Corp. ("Mr. Perry").

This statement relates to Shares (as defined herein) held for the accounts
of two or more private investment funds for which Perry Corp. acts as general
partner and/or managing member of the general partner and/or investment adviser.

ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

The address of the principal business office of each of the Reporting
Persons is 767 Fifth Avenue, New York, New York 10153.

ITEM 2(c) CITIZENSHIP:

- 1) Perry Corp. is a New York corporation; and
- 2) Mr. Perry is a citizen of the United States.

ITEM 2(d) TITLE OF CLASS OF SECURITIES:

Common Stock, \$0.01 par value per share (the "Shares").

ITEM 2(e) CUSIP NUMBER:

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G

91911X104

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b), OR 13D-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- i) Perry Corp. is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940.
- ii) Mr. Perry is a control person of Perry Corp.

ITEM 4. OWNERSHIP:

ITEM 4(a) AMOUNT BENEFICIALLY OWNED:

As of the Date of Event, each of the Reporting Persons may be deemed to be the beneficial owner of 4,175,528 Shares. This number consists of (1) 1,610,800 Shares beneficially owned by the Reporting Persons, (2) 1,947,428 Shares issuable upon conversion of certain bonds beneficially owned by the Reporting Persons, and (3) 617,300 Shares issuable upon exercise of certain options beneficially owned by the Reporting Persons.

ITEM 4(b) PERCENT OF CLASS:

As of the Date of Event, each of the Reporting Persons may be deemed to be the beneficial owner of approximately 4.38% of the total number of Shares outstanding. This percentage was calculated by dividing (i) (A) the total amount of Shares beneficially owned by the Reporting Persons, plus (B) the total amount of Shares issuable upon conversion of certain bonds beneficially owned by the Reporting Persons, plus (C) the total amount of Shares issuable upon exercise of certain options beneficially owned by the Reporting Persons, by (ii) (x) the total number of Shares outstanding as reported by the Issuer in the Quarterly Report, plus (y) the total amount of Shares issuable upon conversion of certain bonds beneficially owned by the Reporting Persons, plus (z) the total amount of Shares issuable upon exercise of certain options beneficially owned by the Reporting Persons

ITEM 4(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

PERRY CORP.

- (i) Sole power to vote or direct the vote
- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

MR. PERRY

- (i) Sole power to vote or direct the vote

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G

- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

The limited partners of (or investors in) each of the private investment funds for which Perry Corp. acts as general partner and/or managing member of the general partner and/or investment adviser have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities held for the accounts of their respective funds in accordance with their respective limited partnership interest (or investment percentages) in their respective funds.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Perry Corp. is the relevant entity for which Mr. Perry may be considered a control person.

Perry Corp. is an investment adviser registered under the Investment Advisers Act of 1940.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

This Item 8 is not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

This Item 9 is not applicable.

ITEM 10. CERTIFICATION:

By signing below each of the Reporting Persons certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURES

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 10, 2006 PERRY CORP.

By: Richard C. Perry
Title: President

By: /s/ Michael C. Neus

Michael C. Neus
Attorney-in-Fact

Date: February 10, 2006 RICHARD C. PERRY

By: /s/ Michael C. Neus

Michael C. Neus
Attorney-in-Fact

EXHIBIT INDEX

- A. Joint Filing Agreement, dated as of February 10, 2006, by and among the Reporting Persons.....

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G/A with respect to the Common Stock, \$0.01 par value, of Valeant Pharmaceuticals International, dated as of February 10, 2006, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.

Date: February 10, 2006 PERRY CORP.

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G

By: Richard C. Perry
Title: President

By: /s/ Michael C. Neus

Michael C. Neus
Attorney-in-Fact

Date: February 10, 2006

RICHARD C. PERRY

By: /s/ Michael C. Neus

Michael C. Neus
Attorney-in-Fact